The following examples illustrate how TumorScope intends to predict response to therapy to aid clinical decision making. In each example, several therapy options were indicated by the physician based on the patient’s demographics and tumor biology.

Preventing Over-treatment

A 35-year-old female patient was diagnosed with HR+/HER2+ breast cancer of 3.8 cm in size and no lymph node metastasis. Her medical oncologist was evaluating neoadjuvant TCH or TCHP therapies as potential treatment. See more

The medical oncologist selected TCHP, although it resulted in pathological complete response (pCR), complete eradication of the tumor, it also resulted in severe side effects. Would TCH – a less toxic regimen – have been a viable option?

TumorScope evaluated these scenarios and predicted that indeed, the patient would likely have had pCR with TCH. Knowing this information beforehand would have prevented the patient’s severe side effects while achieving pCR at the same time.

Preventing Under-treatment

A 60-year-old female patient was diagnosed with HER2+ breast cancer of 2.8 cm in size and no lymph node metastasis. Her medical oncologist was evaluating neoadjuvant TH, TCH or TCHP therapies as potential treatment.  See more

The medical oncologist selected TCH. The patient did not achieve a pathological complete response (pCR), complete eradication of the tumor.

Would any of the two other options have been viable?

TumorScope evaluated these scenarios and predicted that the patient would likely have had pCR with TCHP, but not with TH or TCH. Although TCHP has higher toxicity side effects as compared to TH or TCH, the patient would have: 1) achieved pCR, and 2) had better long-term prognosis (91%) than with the two other therapies (76%).